BMS-641988
BMS-641988
BMS-641988 (pronunciation: B-M-S-641988) is a pharmaceutical drug developed by Bristol-Myers Squibb, a global biopharmaceutical company. The drug is an androgen receptor antagonist that was under investigation for the treatment of prostate cancer.
Etymology
The name "BMS-641988" is a compound of "BMS", an abbreviation for Bristol-Myers Squibb, and "641988", a unique identifier assigned to the drug during its development phase. The etymology of the name reflects the common practice in pharmaceutical research of assigning alphanumeric codes to drugs in the early stages of development.
Mechanism of Action
BMS-641988 works by binding to the androgen receptor, a type of protein that responds to androgens, which are hormones such as testosterone and dihydrotestosterone. By blocking these receptors, BMS-641988 prevents androgens from promoting the growth of prostate cancer cells.
Related Terms
- Androgen receptor antagonist: A type of drug that blocks the effects of androgens, which can stimulate the growth of certain types of cancer cells.
- Prostate cancer: A form of cancer that develops in the prostate, a small gland that produces seminal fluid in men.
- Bristol-Myers Squibb: A multinational biopharmaceutical company that develops and manufactures prescription pharmaceuticals in various therapeutic areas.
See Also
External links
- Medical encyclopedia article on BMS-641988
- Wikipedia's article - BMS-641988
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski